Provided by Tiger Fintech (Singapore) Pte. Ltd.

Exelixis

37.46
+0.65001.77%
Post-market: 37.07-0.3880-1.04%19:39 EDT
Volume:3.81M
Turnover:141.73M
Market Cap:10.08B
PE:18.04
High:37.58
Open:36.47
Low:36.37
Close:36.81
Loading ...

Exelixis Q2 2025 Earnings Call Summary and Q&A Highlights: CABOMETYX and Zanzalutinib Drive Growth

Earnings Call
·
Yesterday

Exelixis EXEL Q2 2025 Earnings Call Transcript

Motley Fool Transcribing
·
Yesterday

Are Exelixis’s (EXEL) Share Buybacks a Vote of Confidence or a Shift in Strategy?

Simply Wall St.
·
02 Aug

Stock Track | Exelixis Shares Soar 5.05% on Promising Renal Cell Carcinoma Treatment Study Update

Stock Track
·
02 Aug

Stock Track | Exelixis Soars 5.05% on Promising Clinical Study Update for Renal Cell Carcinoma Treatment

Stock Track
·
02 Aug

Exelixis and Merck’s Promising Study on Renal Cell Carcinoma Treatment

TIPRANKS
·
02 Aug

UBS Adjusts Price Target on Exelixis to $38 From $43, Maintains Neutral Rating

MT Newswires Live
·
30 Jul

Exelixis falls -16.7%

TIPRANKS
·
30 Jul

Exelixis Price Target Maintained With a $45.00/Share by Guggenheim

Dow Jones
·
29 Jul

Stock Track | Exelixis Shares Plummet 15.5% as Q2 Revenue Miss Overshadows Earnings Beat

Stock Track
·
29 Jul

Exelixis price target lowered to $46 from $48 at Morgan Stanley

TIPRANKS
·
29 Jul

Exelixis (EXEL) Receives a Hold from Stifel Nicolaus

TIPRANKS
·
29 Jul

Exelixis (EXEL) Receives a Hold from Oppenheimer

TIPRANKS
·
29 Jul

Exelixis (EXEL) Gets a Buy from Guggenheim

TIPRANKS
·
29 Jul

S&P 500 Futures Climb In Premarket Trading; Whirlpool, Exelixis Lag

Dow Jones
·
29 Jul

Charles Schwab : Morgan Stanley Raises Target Price to $131.00 From $117.00

THOMSON REUTERS
·
29 Jul

Sarepta Therapeutics Inc : Morgan Stanley Raises Target Price to $20.00 From $15.00

THOMSON REUTERS
·
29 Jul

Baker Hughes Co : Morgan Stanley Raises Target Price to $55.00 From $45.00

THOMSON REUTERS
·
29 Jul

Exelixis’s Cabometyx Gains Strong Market Share in Neuroendocrine Tumors, Exceeding Expectations

TIPRANKS
·
29 Jul

Morgan Stanley Lowers Price Target on Exelixis to $46 From $48, Keeps Overweight Rating

MT Newswires Live
·
29 Jul